Brentuximab Vedotin
About
Therapy type: Targeted therapy
Therapy strategy: target CD30 antigens
Mappings
NCI Thesaurus: Brentuximab Vedotin (ncit:C66944)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone | |
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab Vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab Vedotin, Dacarbazine, Doxorubicin, Vinblastine | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab Vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab Vedotin | |
| Sensitivity (+) | CD30 + | Cutaneous T-cell Lymphoma | Brentuximab Vedotin |